Funding approved for avelumab in combination with axitinib for untreated advanced kidney cancer

KCSN are formal consultants to NICE and part of the process that appraises all new kidney cancer drugs. We are delighted to tell you that, as from today, kidney cancer patients can get NHS funding via the Cancer Drugs Fund for avelumab in combination with axitinib as a first-line treatment for patients with untreated advanced […]

read more

IKCC statement on the negative opinion by the CHMP for the ipilimumab/nivolumab combination

The International Kidney Cancer Coalition (IKCC) have released the following statement in response to the recent negative opinion given by the Committee for Medicinal Products for Human Use (CHMP), on the approval of combination ipilimumab and nivolumab for the frontline treatment of advanced renal cell carcinoma.   Immunotherapy Combination Denied Regulatory Approval in Europe The […]

read more

How treatments have changed for advanced or metastatic renal cell carcinoma (RCC) over the past decade and a look at potential new treatments for the future

During the last decade, the treatment of advanced or metastatic renal cell carcinoma (RCC) was revolutionised with the advent of antiangiogenic drugs and tyrosine-kinase inhibitors. Several agents targeting the vascular endothelial growth factor (VEGF) pathway (sunitinib, bevacizumab, pazopanib, axitinib) or the mammalian target of rapamycin pathway (temsirolimus, everolimus) were since then progressively approved for first-line […]

read more

NICE turns down two kidney cancer drugs

NICE has issued draft guidance this week turning down two treatments for patients with advanced renal cell carcinoma. Kisplyx (lenvantinib) in combination with everolimus has been turned down for previously treated patients due to uncertainties with the clinical evidence. Fotivda (tivozanib) has been rejected as a first line treatment due to uncertainties on whether the […]

read more
Showing all 4 results